We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Pacira Biosciences Inc (PCRX) USD0.001

Sell:$29.19 Buy:$29.21 Change: $0.34 (1.17%)
NASDAQ:0.12%
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$29.19
Buy:$29.21
Change: $0.34 (1.17%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$29.19
Buy:$29.21
Change: $0.34 (1.17%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.

Contact details

Address:
5401 West Kennedy Boulevard, Suite 890
TAMPA
33609
United States
Telephone:
+1 (813) 5536680
Website:
https://www.pacira.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PCRX
ISIN:
US6951271005
Market cap:
$1.33 billion
Shares in issue:
46.50 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Frank Lee
    Chief Executive Officer, Director
  • Charles Reinhart
    Chief Financial Officer
  • Max Reinhardt
    President - Rest of World
  • Daryl Gaugler
    Chief Operating Officer
  • Kristen Williams
    Chief Administrative Officer, Secretary
  • Anthony Molloy
    Chief Legal and Compliance Officer
  • Ronald Ellis
    Chief Strategy Officer
  • Dennis Mcloughlin
    Chief Customer Officer
  • Jonathan Slonin
    Chief Clinical Officer
  • Roy Winston
    Chief Medical Officer and Orthopedic Franchise

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.